Assessment of type I interferon responses as a feature of immunogenic cell death.

Drug Discovery High-Throughput Screening Assays Immunogenic Cell Death Interferon Type I
Automation Biosensor Drug discovery Immunotherapy MX1

Journal

Methods in cell biology
ISSN: 0091-679X
Titre abrégé: Methods Cell Biol
Pays: United States
ID NLM: 0373334

Informations de publication

Date de publication:
2022
Historique:
entrez: 5 9 2022
pubmed: 6 9 2022
medline: 9 9 2022
Statut: ppublish

Résumé

The radiochemotherapy- or chemotherapy-induced stimulation of immunogenic cell death (ICD) affecting malignant cells ignites antitumor immune responses that are clinically relevant as they allow to achieve durable responses beyond treatment discontinuation. The mechanistic exploration of ICD and the discovery of agents and interventions that are endowed with the capacity to elicit ICD is of the utmost importance. Here, we describe an assay for the assessment of type I interferon (IFN) production, which is one of the salient features of ICD. Biosensor cells that express GFP under the control of the IFN-inducible MX dynamin like GTPase 1 (MX1) gene promoter are employed, and the fluorescent signal is assessed by automated microscopy. The described workflow is automation-friendly, rendering it compatible with high-throughput screening (HTS) for drug discovery.

Identifiants

DOI: 10.1016/bs.mcb.2021.12.028 PMID: 36064220
pubmed: 36064220
pii: S0091-679X(21)00133-3
doi: 10.1016/bs.mcb.2021.12.028
pii:
doi:

Substances chimiques

Interferon Type I 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-143

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest G.K. and O.K. are cofounders of Samsara Therapeutics. G.K. is a founder of everImmune and Therafast Bio.

Auteurs

Sabrina Forveille (S)

Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France.

Allan Sauvat (A)

Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France.

Shuai Zhang (S)

Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France; Université Paris Sud, Paris Saclay, Faculty of Medicine, Kremlin Bicêtre, France.

Liwei Zhao (L)

Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France.

Guido Kroemer (G)

Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China; Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden. Electronic address: kroemer@orange.fr.

Oliver Kepp (O)

Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France. Electronic address: captain.olsen@gmail.com.

Articles similaires

Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease.

Adrian Gervais, Paul Bastard, Lucy Bizien et al.
1.00
Humans Interferon Type I Ross River virus Encephalitis, Tick-Borne Antibodies, Neutralizing

A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery.

Philip R Coryell, Paul B Hardy, Susan Chubinskaya et al.
1.00
Humans Chondrocytes Osteoarthritis Matrix Metalloproteinase 13 Drug Discovery

Multi-layer graph attention neural networks for accurate drug-target interaction mapping.

Qianwen Lu, Zhiheng Zhou, Qi Wang
1.00
Neural Networks, Computer Drug Discovery Humans Drug Repositioning

TamGen: drug design with target-aware molecule generation through a chemical language model.

Kehan Wu, Yingce Xia, Pan Deng et al.
1.00
Drug Design Models, Chemical Endopeptidase Clp Drug Discovery Humans

Classifications MeSH

questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Découverte de médicament › Assessment of type I interferon responses as a...
questionsmedicales.fr › Techniques d'investigation › Tests de criblage à haut débit › Assessment of type I interferon responses as a...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Mort cellulaire immunogène › Assessment of type I interferon responses as a...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Interféron de type I › Assessment of type I interferon responses as a...